We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Poseida Therapeutics Inc | NASDAQ:PSTX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.07 | -2.71% | 2.51 | 2.51 | 2.52 | 2.61 | 2.495 | 2.57 | 132,967 | 16:11:34 |
From Jun 2023 to Jun 2024
By Sabela Ojea
Shares of Poseida Therapeutics on Monday climbed after the company said it received positive early results from the phase 1 trial for a blood cancer treatment.
At 9:43 a.m. ET, shares were up 21% at $3.83. The stock has, however, dropped 75% in the past 12 months.
The clinical-stage cell and gene therapy company said its early P-BCMA-ALLO1 clinical results inspire it to further develop the treatment for relapsed-refractory multiple myeloma in partnership with Roche.
Last year, Poseida said it signed a strategic collaboration with the biotechnology company Roche.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
December 11, 2023 10:16 ET (15:16 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Poseida Therapeutics Chart |
1 Month Poseida Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
